Introduction {#j_bjmg-2018-0006_s_001}
============

Type 2 diabetes mellitus (T2DM) is a highly prevalent disease worldwide. The T2DM is featured with relative higher level of blood glucose than normal subjects, moreover it manifested insulin resistance in several conditions \[[@j_bjmg-2018-0006_ref_001]\]. The etiology of T2DM is not well understood, but it is now generally believed that this disease may be related to the genetic, personal and environmental factors. Among these, genetic polymorphisms in nuclear genes have been reported to be associated with T2DM \[[@j_bjmg-2018-0006_ref_002]\]. However, the maternally inherited pattern of T2DM may also be frequent \[[@j_bjmg-2018-0006_ref_003]\], highlighting the importance of mitochondrial disfunction in T2DM. In fact, approximately 85.0% of mitochondrial diabetes cases are associated with the A3243G mutation in the *tRNA^Leu(UUR)^* gene \[[@j_bjmg-2018-0006_ref_004]\], moreover, some other point mutations, such as T3264C and T3271C in the *tRNA^Leu(UUR)^* gene, are reported in patients with DM \[[@j_bjmg-2018-0006_ref_005], [@j_bjmg-2018-0006_ref_006]\]. These mutations impaired the mitochondrial protein synthesis, subsequently affecting the oxidative phosphorylation (OXPHOS) complexes, thus causing the mitochondrial dysfunction responsible for DM \[[@j_bjmg-2018-0006_ref_007]\]. As a result, the *mt-tRNA* genes have become novel targets for investigation the relationship between mitochondrial dysfunction and T2DM.

However, it come to our attention that the genotype-phenotype relationship between DM and *mt-tRNA* gene mutations was still controversial. At the same time, many T2DM associated mt-tRNA variants have been reported on PubMed. We have noticed that most of them were common genetic variations becosause they did not meet the pathogenicity scoring system proposed by Yarham et al. \[[@j_bjmg-2018-0006_ref_008]\], such as the association between *tRNA^Phe^* C628T mutation and hearing loss \[[@j_bjmg-2018-0006_ref_009]\]. Distinguishing the polymorphisms and disease associated *mtDNA* mutations is important, both for clinical physician and genetic scientists.

In the current investigation, we evaluated the association between a recent reported mt-tRNA^Gly^ T10003C mutation and DM. First of all, we performed a systematic database search for the frequency of this mutation; second, we also reassessed the conservation index (CI) of the T10003C mutation, and finally, we performed a case-control study to screen this mutation in 500 unrelated DM patients and 300 healthy individuals.

Materials and methods {#j_bjmg-2018-0006_s_002}
=====================

**Database Searches**. With the purpose of comparing different reports regarding the T10003C mutation, we performed a systematic review for this mutation using the Google scholar, PubMed Central and Human MITOMAP database. The literature search was carried out using these combined keywords: "mitochondrial T10003C mutation" or "mitochondrial T10003C variant." We excluded studies if the crucial data were not reported in original paper.

**Evolutionary Conservation Analysis**. To understand the potential pathogenic role of the T10003C mutation, we analyzed the CI of this mutation. Briefly, 10 vertebrate *mt-tRNA^Gly^* gene sequences were selected for this analysis. The conservation index (CI) was then calculated by comparing the human nucleotide variants with nine other vertebrates \[[@j_bjmg-2018-0006_ref_010]\]. We regarded the CI as the percentage of species from the list of 10 different primates that have the wild-type at the corresponding position. The CI \>75.0% was proposed to have a functional potential.

**Haplogroup Analysis**. We used the Phylotree ([www.phylotree.org](http://www.phylotree.org)) to determine the haplogroup status of the T10003C mutation \[[@j_bjmg-2018-0006_ref_011]\].

**Prediction of the Secondary Structure of tRNA^Gly^ With and Without the T10003C Mutation**. We used the RNA Fold Webserver program (<http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi>) to predict the secondary structures of the wild-type version of mt-tRNA^Gly^ and the mutant carrying the T10003C mutation \[[@j_bjmg-2018-0006_ref_012]\].

**Mutational Analysis of the T10003C Mutation**. Five hundred unrelated DM patients including 250 male and 250 females were recruited from the Department of Endocrinology and Metabolism, People's Hospital of Zhengzhou University, Zhengzhou, Zhengzhou, Henan Province, People's Republic of China. The age ranged from 50 to 80 years with the median at 61. In addition, 300 healthy, age- and gender-matched controls, obtained from the same area were also enrolled in this study. This study was approved by the Ethics Committee of the People's Hospital of Zhengzhou University.

The clinical diagnosis of DM was according to the American Diabetes Association criteria: the level of fasting plasma glucose of ≥7.0 mmol/dL, or the level of the oral glucose tolerance ≥1.11 mmol/dL, or Hb A~1c~ concentration ≥6.5% \[[@j_bjmg-2018-0006_ref_013]\]. Determination of the T10003C mutation was performed by polymerase chain reaction (PCR) amplification and sequencing analysis of the targeted region spanning the *mt-tRNA^Gly^* gene. The following primers were used: forward 5'-TCT CCA TCT ATT GAT GAG GGT CT-3'; reverse 5'-AAT TAG GCT GTG GGT GGT TG-3'; after PCR amplification, the fragment was purified and subsequently analyzed by direct sequencing in an ABI PRISM® 3700 automatic DNA sequencer using the BigDye Terminator Cycle sequencing reaction kit (Applied Biosystems Inc., Foster City, CA, USA). The data was then compared with the reversed consensus Cambridge sequence (GenBank Accession No. NC_12920) \[[@j_bjmg-2018-0006_ref_014]\].

**Statistical Analyses**. We used the Statistical Package for the Social Sciences (SPSS), version 17.0 software to analyze the statistical significance (SPSS Inc., Chicago, IL, USA). Fisher's exact test was performed to evaluate the differences in categorical variables, and a value of *p* \<0.05 was regarded as statistically significant.

Results {#j_bjmg-2018-0006_s_003}
=======

**Relationship Between the T10003C Mutation and Diabetes Mellitus**. As a result, two potential articles concerning the association between the T10003C mutation and DM have been identified. After carefully reading the complete manuscripts, we found that one of them described a Chinese family with T2DM \[[@j_bjmg-2018-0006_ref_015]\], while another paper, which met our inclusion criteria, reported a Chinese family with T2DM and deafness \[[@j_bjmg-2018-0006_ref_016]\]. However, after carefully checking these reported families, it looked as if they were from the same family.

**Evolutionary Conservation Analysis of the T10003C Mutation**. With the purpose of understanding the molecular basis of the T10003C mutation, we performed the evolutionary conservation analysis for this mutation between different species. As shown in [Figure 1](#j_bjmg-2018-0006_fig_001){ref-type="fig"}, the T10003C mutation occurred in the D-stem of tRNA^Gly^ (position 13). Nucleotide at that position was not very conserved (CI = 50.0%), suggesting that the T to C transition at 10003 position may not be involved in the pathogenesis of DM.

![Sequence alignment of the *tRNA^Gly^* gene from different species; the arrow indicates position 13 corresponding to the T10003C mutation.](bjmg-21-053-g001){#j_bjmg-2018-0006_fig_001}

**Phylogenetic Analysis of the T10003C Mutation**. We further performed a haplogroup analysis for the T10003C mutation, based on the Phylotree. We noticed that the T10003C mutation belonged to the East Asian mitochondrial haplogroup M11b \[[@j_bjmg-2018-0006_ref_011]\].

**The T10003C Mutation did not Alter the Structure of tRNA^Gly^**. To test whether T10003C mutation caused the tRNA^Gly^ structure alteration, the sequence of the wild-type and the mutant carrying the T10003C mutation were predicted using RNA Fold software. As shown in [Figure 2](#j_bjmg-2018-0006_fig_002){ref-type="fig"}, the T10003C mutation did not change the secondary structure of tRNA^Gly^, indicating that this mutation had little effect on tRNA^Gly^ folding, reinforcing the idea that this mutation was not pathogenic.

![Prediction of the secondary structure of the *tRNA^Gly^* gene with and without the T10003C mutation.](bjmg-21-053-g002){#j_bjmg-2018-0006_fig_002}

**Screening of the T10003C Mutation in 500 Unrelated DM Patients**. To investigate the allelic frequency of the T10003C mutation in the general population, we used a PCR-Sanger sequence to detect this mutation in 500 unrelated DM patients and 300 healthy controls. However, we failed to identify any mutations in the *tRNA^Gly^* gene, suggesting that this mutation may be a rare event in the human population.

Discussion {#j_bjmg-2018-0006_s_004}
==========

In this study, we investigated the potential pathogenic role of T2DM associated tRNA^Gly^ T10003C mutation. Mitochondria are the powerful machine in cells whose primary role is to generate adenosine triphosphate (ATP), through OXPHOS. More recently, the role of the mitochondrial dysfunction in the pathogenesis of DM has been studied extensively. Alterations in mitochondrial function in human β cells resulted in the impaired glucose-stimulated insulin secretion. Mutations in mtDNA, especially *mt-tRNA* genes, found to be associated with DM. In particular, one of the most common pathogenic mtDNA mutation was A3243G in the *tRNA^Leu(UUR)^* gene. This mutation was reported to decrease the steady-state level of the *tRNA^Leu(UUR)^* and resulted with the impairment of amino-acylation ability \[[@j_bjmg-2018-0006_ref_017]\], and subsequently, mitochondrial protein synthesis failed \[[@j_bjmg-2018-0006_ref_018]\]. However, there is a number of mt-tRNA variations that were wrongly classified as a "pathogenic" mutation, such as the C628T variant \[[@j_bjmg-2018-0006_ref_009], [@j_bjmg-2018-0006_ref_019]\].

With this regard, this study reassessed the possible association between the T10003C mutation and DM. Database searches for the presence of this mutation led us to identify two potential records that were mentioned in the results sections \[[@j_bjmg-2018-0006_ref_015], [@j_bjmg-2018-0006_ref_016]\]. Mutational analysis of the proband from the maternally inherited DM identified a set of polymorphisms; some of these were obviously pathogenic in the human population, for example, the G15924A mutation in the *tRNA^Thr^* gene, was reported to be a fatal infantile respiratory enzyme deficiency- associated pathogenic mutation \[[@j_bjmg-2018-0006_ref_020]\]. Moreover, the 12S rRNA T1095C mutation was a deafness associated primary mutation \[[@j_bjmg-2018-0006_ref_021]\], whereas the A6 A8701G mutation was found to be associated with cardiomyopathy in the Han Chinese population \[[@j_bjmg-2018-0006_ref_022]\]. Therefore, it seemed that beside the T10003C mutation, other mutations may also contribute to DM in this Chinese family.

At the molecular level, the T10003C mutation localized at the D-stem of the *tRNA^Gly^* gene (position 13), was not very conserved among different species ([Figure 1](#j_bjmg-2018-0006_fig_001){ref-type="fig"}). Furthermore, to explore the structure to function relations, we used the RNA Fold Webserver program to predict the optimal secondary structure of tRNA^Gly^ through free energy minimization. As shown in [Figure 2](#j_bjmg-2018-0006_fig_002){ref-type="fig"}, it was quite obvious that T10003C mutation failed to cause the alternation of tRNA^Gly^ structure, moreover, we did not detect the T10003C mutation in 500 unrelated DM patients and 300 control subjects, suggesting that it may be a genetic polymorphism rather than a pathogenic mutation.

In conclusion, there was no direct evidence to support the association between the T10003C mutation and DM. Further studies including larger samples and functional analyses are needed to verify this conclusion.
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